Drug Profile
NED 170
Alternative Names: NED-170Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator NED Biosystems
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for clinical-Phase-Unknown development in Cancer(Combination therapy) in USA (PO)
- 29 Apr 2019 NED Biosystems plans a phase I/IIa trial for Breast cancer and Cholangiocarcinoma in the second half of 2019
- 07 Feb 2019 NED Biosystems has patent protection for NED 170 in USA